3-D Matrix, Inc., based in Waltham, Massachusetts, is a wholly owned subsidiary of 3-D Matrix, Ltd., Tokyo, Japan. The 3-D Matrix Group develops and manufactures a family of peptide biomaterials under the trade name PuraMatrix® for use in clinical applications and life science research.
3-D Matrix has driven development of its technology using a “lean company” model, leveraging the activities of its founding scientists at MIT, the company’s multiple collaborations with leading companies, outsourced manufacturing to contract facilities, and distribution agreements for its commercial products. This structure has proven extremely efficient at driving pre-clinical proof-of-concept studies while commercializing products with the life science and drug discovery research communities. The company intends to build its business development and scientific staff to mirror the near-term opportunities driven by partnerships as well as internal developments.
John Maki is President and CEO of Vicus Therapeutics, LLC. He was previously Managing Director of Technology Directors, Inc. and before Managing Director of the Audax Group. He has been a Principal at Bain Capital and a Consultant at Bain & Company. Mr. Maki has a A.B. from Harvard University. He currently serves on the boards of 3-D Matrix, of Addition Technology, an ophthalmic device company, and of Vicus Therapeutics. Mr. Maki also serves on the Board of Trustees of BIO NJ.